SOV Therapeutics

SOV Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for rare metabolic diseases, with a primary focus on urea cycle disorders (UCDs). The company's lead programs aim to improve the management of hyperammonemia through optimized delivery and formulation of ammonia-scavenging agents. SOV Therapeutics is advancing SOV2012, a taste-masked formulation of sodium phenylbutyrate, to address the significant treatment burden and palatability issues associated with current standard-of-care therapies. By focusing on patient-centric drug development, the company seeks to enhance adherence and clinical outcomes for patients with life-threatening genetic conditions. Headquartered in Irvine, California, the firm is led by experienced industry veterans with a track record in successful drug development.